VYNE Therapeutics (NASDAQ:VYNE) Trading Up 0.4% – Here’s Why

VYNE Therapeutics Inc. (NASDAQ:VYNE)’s share price was up 0.4% during mid-day trading on Monday . The company traded as high as $0.6185 and last traded at $0.6037. Approximately 170,707 shares traded hands during trading, a decline of 7% from the average daily volume of 183,039 shares. The stock had previously closed at $0.6010.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on VYNE. Wall Street Zen raised shares of VYNE Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, February 2nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of VYNE Therapeutics in a research note on Wednesday, January 21st. Three equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, VYNE Therapeutics has a consensus rating of “Reduce” and a consensus target price of $4.50.

VYNE Therapeutics Stock Up 0.4%

The firm has a market cap of $20.12 million, a PE ratio of -0.77 and a beta of 1.94. The company’s 50 day moving average price is $0.59 and its two-hundred day moving average price is $0.49.

VYNE Therapeutics (NASDAQ:VYNE) last announced its earnings results on Friday, February 27th. The company reported ($0.15) earnings per share for the quarter. VYNE Therapeutics had a negative net margin of 4,646.14% and a negative return on equity of 74.86%. The firm had revenue of $0.13 million during the quarter. On average, analysts expect that VYNE Therapeutics Inc. will post -0.97 earnings per share for the current fiscal year.

Institutional Investors Weigh In On VYNE Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. KVP Capital Advisors LP purchased a new stake in shares of VYNE Therapeutics in the fourth quarter valued at $290,000. XTX Topco Ltd purchased a new stake in shares of VYNE Therapeutics in the fourth quarter valued at $46,000. ADAR1 Capital Management LLC purchased a new stake in shares of VYNE Therapeutics in the fourth quarter valued at $147,000. Anson Funds Management LP purchased a new stake in shares of VYNE Therapeutics in the fourth quarter valued at $739,000. Finally, Nantahala Capital Management LLC purchased a new stake in shares of VYNE Therapeutics in the fourth quarter valued at $580,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.